Does PTN pay a dividend and is it safe?

Palatin Technologies Inc. (PTN) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / PTN / dividends

INM (47) BFRG (32) CMMB (31) MBRX (34) ⌘ Pro Terminal →

Palatin Technologies Inc. (PTN) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Where is PTN trading relative to its 50-day, 200-day, and 52-week technical levels?

PTN last traded at $4.99 (-0.20% on volume of 30,717 shares), positioning the stock -44.25% below its 50-day simple moving average ($8.95) and -64.15% below its 200-day simple moving average ($13.92). Across its 52-week range of $4.51 to $31.00, PTN sits at the 1.8% percentile with a 14-day RSI of 26.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($4.37 to $5.61).

$4.99 -0.20% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.98

Palatin Technologies Inc. (PTN) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $8.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PTN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PTN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Palatin Technologies Inc. (NASDAQ: PTN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $4.99 (-0.20% 1D, market cap $8.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PTN ranks #611 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PTN compare to INM and BFRG in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PTN carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INM (InMed Pharmaceuticals Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $8.8M) and BFRG (Bullfrog AI Holdings Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $9.0M). Among the 5-stock peer group, PTN leads on earnings multiple (N/A) while PTN leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PTN?

▼

Per PTN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000911216), Palatin Technologies Inc. generated $48.9M in revenue (+988.8% YoY), -$17.3M in net income, and -$21.3M in free cash flow against $17.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.98 (-0.23%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PTN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (35/100 Composite)

🔍 WHY PTN SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (29% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 26.2 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$8.19-32.6% Next Q

Q2 (-2Q)

Grade D$5.52-13.6% Next Q

Q3 (-1Q)

Grade E$4.77+4.6% Next Q

Current

Grade D-$4.99-8.5% Hist 90D α

Trajectory: D (43) → D- (35)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PTN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PTN currently carries a cautious 35/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.95) and Max Pain ($5.24) forces dealer call-delta covering toward $32.55.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PTN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PTN Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 35%NO 65%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PTN)

✓Walkthrough of PTN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PTN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -75.10%🛡️ HOLDING TREND SUPPORT

2026-11-03O $4.93H $5.00L $4.93C $4.99VOL 16.0K

SUP: $4.04SMA50: $8.95SMA200: $13.92

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PTN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PTN Butterfly Map → + Track PTN →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +988.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PTN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PTN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PTN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PTN)

Health Care Rank #611 of 1015 ⚔️ INM vs PTN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PTN vs. INM, BFRG, CMMB, MBRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Palatin Technologies Inc. (PTN) ranks #611 by composite RQD confidence (35/100, grade D-) and #901 by equity capitalization ($8.9M). Within this direct 5-issuer industry benchmark cohort, PTN leads on earnings valuation at N/A trailing P/E, while PTN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. INM currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with PTN at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PTN ACTIVE Palatin Technologies Inc.	D-	35/100	—	—	-35.0%	-0.20%	$8.9M	Benchmark Subject
INM InMed Pharmaceuticals Inc.	D	47/100	—	34.5%	-35.0%	+1.88%	$8.8M	/inm-vs-ptn →
BFRG Bullfrog AI Holdings Inc.	E	32/100	—	18.8%	-35.0%	+1.78%	$9.0M	/bfrg-vs-ptn →
CMMB Chemomab Therapeutics Ltd.	E	31/100	—	—	-35.0%	+1.72%	$9.3M	/cmmb-vs-ptn →
MBRX Moleculin Biotech Inc.	E	34/100	—	—	-35.0%	+5.32%	$8.3M	/mbrx-vs-ptn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0000911216 ↗

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Palatin Technologies Inc. (PTN) reported GAAP revenue of $48.9M (+988.8% vs. FY2024 revenue of $4.5M , and +907.2% cumulative change since FY2023) , GAAP net income of -$17.3M, operating cash flow of -$21.3M, and free cash flow of -$21.3M (+32.4% YoY). On the balance sheet, PTN closed FY2025 with $17.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$48.9M	-$17.3M	-$21.3M	-$21.3M	$17.9M	—
FY2024 (FY)	2024-06-30	$4.5M	$29.7M	-$31.5M	-$31.5M	$4.3M	—
FY2023 (FY)	2023-06-30	$4.9M	$36.2M	-$29.3M	-$29.3M	—	—

3. PTN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PTN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PTN compare to INM and BFRG in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PTN?

Where is PTN trading relative to its 50-day, 200-day, and 52-week technical levels?

PTN last traded at $4.99 (-0.20% on volume of 30,717 shares), positioning the stock -44.25% below its 50-day simple moving average ($8.95) and -64.15% below its 200-day simple moving average ($13.92). Across its 52-week range of $4.51 to $31.00, PTN sits at the 1.8% percentile with a 14-day RSI of 26.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($4.37 to $5.61).

Direct Sub-Reports: PTN RQD Cockpit PTN 12M Forecast PTN Earnings & Move PTN Dividends & DRIP PTN Insiders & 13F PTN Whale Options PTN Profit Sankey PTN News & Why

ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ SEC XBRL & RQD VERIFIED

PTN — Palatin Technologies Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Palatin Technologies Inc. (PTN) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $4.99 (-0.20% 1D, market capitalization $8.9M).

Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Palatin Technologies Inc. (PTN) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), Palatin Technologies Inc. (PTN) reported $48.9M in annual revenue (up from $4.5M in FY2024, +988.8% YoY) and -$17.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($4.9M revenue, $36.2M net income) through FY2025, PTN scaled operating cash flow to -$21.3M and free cash flow to -$21.3M, backed by $17.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $4.51 – $31.00 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

There are no upstream or downstream links, no sector correlation mapping, and no proprietary signals recorded for PTN. The stock's sector placement (Health Care, Biotechnology: Pharmaceutical Preparations) is the only structural context available. Investors should watch for whether any pharma-sector developments referenced in news coverage translate into concrete counterparty relationships, though the source data cannot confirm this.

Key Question #1: Can PTN sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $48.9M and free cash flow of -$21.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is PTN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PTN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Palatin Technologies Inc. (PTN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PTN Debate Forum (3) ↓

🟡 MARKET WIRE www.debelegger.nl • 1d ago

Palatin Technologies (PTN) Stock Price, Chart & Analysis

www.debelegger.nl report covering Palatin Technologies Inc. (PTN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

Palatin Technologies, Inc. (PTN) Seasonal returns chart

Yahoo Finance UK report covering Palatin Technologies Inc. (PTN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

Big Pharma’s Obesity Shopping Spree Is Moving Beyond GLP-1s. Palatin May Fit the Pattern (NASDAQ: PTN)

Investing.com report covering Palatin Technologies Inc. (PTN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Kalkine • 1d ago

Palatin Technologies, Inc. Common Stock (NASDAQ: PTN) Share Price, PTN Stock News, PTN Share Price & Updates

Kalkine report covering Palatin Technologies Inc. (PTN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Palatin Technologies Q1 2027 Earnings Date and Estimates

MarketBeat report covering Palatin Technologies Inc. (PTN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.siam.in/ • 1d ago

Palatin Technologies (PTN) Ticks Up 1.42% to $5.00 as Shares Press Against Near-Term Resistance - PSAR Stop

https://www.siam.in/ report covering Palatin Technologies Inc. (PTN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago

Palatin Technologies (PTN) Edges 0.33% Lower to $5.99, Holding Midpoint of Support-Resistance Band - Reversal Setup Alerts

https://www.dars.gov.et/ report covering Palatin Technologies Inc. (PTN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PTN Bull vs. Bear Conversation Board — What's Your Call at $4.99?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PTN 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $6.10 (+22.0%)

📌 Pinned Debate

The news feed flags a possible obesity-pipeline fit for big pharma, and the Roarable RQD rating shows a 1.0 beta and a 2.5 Altman Z-Sco

Picked up a starter position in PTN in my $100K Virtual Cash book at $5.00. The news feed flags a possible obesity-pipeline fit for big pharma, and the Roarable RQD rating shows a 1.0 beta and a 2.5 Altman Z-Score that places the balance sheet outside distress territory.. Trading inside a $4.51–$31.00 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

ArenaChamp_24 🐂 BULL

@QuantViper Agree on the RQD 35/100 quality, though with 1.0 beta I'm scaling in with half-size at $5.00 and keeping dry powder in case we test $4.65.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $4.20 (-16.0%)

Spot @ $5.00

Operating income and free cash flow were negative in every reported period, ROIC is -35%, and the Piotroski F-Score of 1/9 signals weak

Here is the bear case nobody on the bull side wants to address on PTN: Operating income and free cash flow were negative in every reported period, ROIC is -35%, and the Piotroski F-Score of 1/9 signals weak fundamental quality.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.